A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs GS 9876 (Primary) ; Filgotinib
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 16 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Sep 2017.
- 16 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2017.
- 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.